论文部分内容阅读
目的探讨多西紫杉醇联合同步调强适形放疗对局部晚期鼻咽癌患者的临床疗效,为临床治疗提供参考。方法选择2011年6月—2014年6月42例局部晚期鼻咽癌患者,按照随机数字表法分为观察组与对照组,各21例。对照组男性14例,女性7例;平均年龄(52.77±6.11)岁;观察组男性15例,女性6例;平均年龄(53.15±5.47)岁。对照组使用5-氟尿嘧啶联合奈达铂同步调强适形放疗治疗,观察组使用奈达铂联合多西紫杉醇同步调强适形放疗治疗,对比2组治疗后近期缓解率、毒副反应、鼻咽大体肿瘤靶区体积缩小率。结果观察组完全缓解率为71.43%,近期有效率为90.48%,与对照组66.67%、85.71%比较差异无统计学意义(χ2完全缓解率=0.891,P=0.251;χ2近期有效率=0.922,P=0.185);观察组化疗前后鼻咽大体肿瘤靶区体积分别为(49.21±6.15)cm3、(36.14±5.07)cm3,体积缩小率为26.56%,均与对照组比较差异无统计学意义(P>0.05);观察组恶心或呕吐、中性粒细胞减少、食欲减退、腹胀Ⅲ~Ⅳ度发生率均明显低于对照组,差异有统计学意义(P<0.05)。结论多西紫杉醇联合同步调强适形放疗治疗局部晚期鼻咽癌效果显著,毒副作用可接受,值得临床推广应用。
Objective To investigate the clinical efficacy of docetaxel combined with concurrent intensity-modulated conformal radiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC), and provide a reference for clinical treatment. Methods Forty-two patients with locally advanced nasopharyngeal carcinoma from June 2011 to June 2014 were divided into observation group and control group according to the random number table method, with 21 cases in each group. The control group of 14 males and 7 females; mean age (52.77 ± 6.11) years; the observation group of 15 males and 6 females; mean age (53.15 ± 5.47) years. The control group was treated with 5-fluorouracil plus nedaplatin concurrently with intensity-modulated conformal radiotherapy. The observation group was treated with nedaplatin combined with docetaxel simultaneously with intensity-modulated conformal radiotherapy. The rates of immediate remission, side effects, nasal toxicity Pharyngeal tumor volume target volume reduction rate. Results The complete remission rate was 71.43% in the observation group, the effective rate was 90.48% in the short-term observation group, which was not significantly different from 66.67% and 85.71% in the control group (χ2 = 0.891, P = 0.251; P = 0.185). The volumes of nasopharyngeal tumor before and after chemotherapy in the observation group were (49.21 ± 6.15) cm3 and (36.14 ± 5.07) cm3, respectively, with a volumetric reduction rate of 26.56%. There was no significant difference between the two groups P> 0.05). The nausea or vomiting, neutropenia, loss of appetite and the incidence of abdominal distension Ⅲ ~ Ⅳ in the observation group were significantly lower than those in the control group (P <0.05). Conclusions Docetaxel combined with concurrent intensity-modulated conformal radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma has obvious effect and toxic side effects and is worthy of clinical application.